MAY 28, 2014 12:00 PM PDT


  • Associate Professor of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine
      Dr. Van Der Pol has been involved in laboratory-based epidemiologic and behavioral research in the field of sexually transmitted infections (STI) and HIV for more than 30 years.  She has extensive experience with development and evaluation of molecular diagnostic assays and is internationally recognized as an expert in this field. She participated in writing the CDC STD Diagnostic Laboratory Guidelines and the WHO STD/HIV Laboratory Diagnostics Manual. Dr. Van Der Pol has also evaluated novel methods for STI detection and developed molecular diagnostic assay for the identification of organisms for which no FDA-approved assays exists.  Her laboratory developed and evaluated a molecular assay for the detection of Trichomonas vaginalis DNA 12 years before such an assay would become commercially available. She also assessed the feasibility of using self-obtained vaginal swabs collected in non-clinical settings for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.  This is now the CDC recommended optimal sample type for diagnosis of these infections.  More recently she demonstrated the feasibility of patient collected rectal samples, again in a non-clinical setting, for use with chlamydia and gonorrhea testing.  In addition to her work in the US, Dr. Van Der Pol has spent 2 decades working in sub-Saharan Africa providing technology transfer, capacity building and quality improvement training.  She is currently serving as a consultant to the CDC for laboratory strengthening efforts in the Caribbean region.


    The CDC has recently released the Recommendations for Laboratory Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. As a result of advances in molecular diagnostics, the current recommendations are substantially different from the previous version published in 2002. Dr. Van Der Pol will provide data regarding the importance of chlamydia and gonorrhea screening and describe the process by which the current guidelines were developed. The application of the guidelines in both laboratories and in clinical settings will be described. Recommendations for testing non-genital (e.g. ano-rectal and oropharyngeal) samples will also be discussed. Adoption of the CDC recommendations will improve sexually transmitted infection control efforts and may help move screening toward a normative, sexual health maintenance practice.

    The learner will be able to choose the appropriate type of assay to use for chlamydia/gonorrhea screening.
    The learner will be able to provide appropriate screening options for patients who report anal or oral sex.

    Show Resources
    Loading Comments...